- Home
- COOK vs YMAB Comparison
COOK vs YMAB Comparison
Compare COOK & YMAB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- COOK
- YMAB
- Stock Information
- Founded
- COOK 1985
- YMAB 2015
- Country
- COOK United States
- YMAB United States
- Employees
- COOK N/A
- YMAB N/A
- Industry
- COOK Wholesale Distributors
- YMAB Biotechnology: Pharmaceutical Preparations
- Sector
- COOK Consumer Discretionary
- YMAB Health Care
- Exchange
- COOK Nasdaq
- YMAB Nasdaq
- Market Cap
- COOK 209.0M
- YMAB 192.4M
- IPO Year
- COOK 2021
- YMAB 2018
- Fundamental
- Price
- COOK $1.41
- YMAB $8.51
- Analyst Decision
- COOK Buy
- YMAB Buy
- Analyst Count
- COOK 7
- YMAB 11
- Target Price
- COOK $2.29
- YMAB $15.02
- AVG Volume (30 Days)
- COOK 272.6K
- YMAB 1.5M
- Earning Date
- COOK 08-06-2025
- YMAB 08-08-2025
- Dividend Yield
- COOK N/A
- YMAB N/A
- EPS Growth
- COOK N/A
- YMAB N/A
- EPS
- COOK N/A
- YMAB N/A
- Revenue
- COOK $579,453,000.00
- YMAB $85,385,000.00
- Revenue This Year
- COOK $0.06
- YMAB N/A
- Revenue Next Year
- COOK $3.18
- YMAB $15.23
- P/E Ratio
- COOK N/A
- YMAB N/A
- Revenue Growth
- COOK N/A
- YMAB N/A
- 52 Week Low
- COOK $1.28
- YMAB $3.55
- 52 Week High
- COOK $3.97
- YMAB $16.11
- Technical
- Relative Strength Index (RSI)
- COOK 32.95
- YMAB 81.64
- Support Level
- COOK $1.52
- YMAB $4.16
- Resistance Level
- COOK $1.76
- YMAB $8.54
- Average True Range (ATR)
- COOK 0.10
- YMAB 0.24
- MACD
- COOK -0.05
- YMAB 0.47
- Stochastic Oscillator
- COOK 7.84
- YMAB 99.32
About COOK Traeger Inc.
Traeger Inc designs, sources, sells, and supports wood pellet fueled barbeque grills sold to retailers, distributors, and direct to consumers. It produces and sells the pellets used to fire the grills and also sells Traeger-branded rubs, spices, and sauces, as well as grilling accessories including covers, barbeque tools, trays, liners, and merchandise. The company's geographical segments include North America and the Rest of the world, of which majority of revenue is from North America.
About YMAB Y-mAbs Therapeutics Inc.
Y-mAbs Therapeutics Inc is a commercial-stage biopharmaceutical company. It is mainly engaged in the development and commercialization of novel, antibody-based therapeutic products for the treatment of cancer. DANYELZA, is the first FDA-approved product of the company which is a recombinant humanized immunoglobulin G, subtype 1k, or IgG1k, monoclonal antibody or mAb that targets ganglioside GD2, which is expressed in various neuroectoderm-derived tumors and sarcomas.